Concord Drugs Limited

BSE: CONCORD · Pharmaceuticals · sector

₹65.07BSE close 2026-10-26

Key numbers

Market cap₹86 cr

Price₹65.07

52w high / low₹93 / ₹61

P/E36.4xSector median 27.9x

P/B1.8xSector median 2.9x

Book value₹36.8

Dividend yield–Sector median 0.48%

ROE5.0%Sector median 11.7%

ROCE7.2%Sector median 12.3%

OPM6.7%Sector median 14.0%

Debt / equity0.28xSector median 0.16x

EV/EBITDA17.0xSector median 18.6x

Interest cover2.8x

Current ratio2.53x

Sales growth 3y+15.3%Sector median +9.6%

Profit growth 3y+5.8%Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹14 cr (FY26): borrowings are higher by ₹13 cr.
Operating profit covered interest 2.8x in the last 12 months.
Other income was 2% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹65.07 on 2026-10-26: -29.7% from the 52-week high, +6.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹90.08 · low ₹27.46

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	10	14	10	17	38	21
EBITDA	1	1	1	1	1	2
OPM %	10.0%	7.5%	10.7%	5.4%	3.9%	10.9%
Other income	0	0	0	0	0	0
Net profit	0	0	0	0	1	1
EPS (₹)	0.04	0.12	0.31	0.16	0.47	0.85
Revenue YoY					+264.7%	+53.9%
Profit YoY					+1,225.0%	+825.0%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	59	51	43	45	79	86
EBITDA	6	4	4	4	5	6
Net profit	2	1	0	0	1	2
EPS (₹)	1.82	0.96	0.42	0.34	0.95	1.79
Revenue growth		-13.0%	-15.7%	+4.6%	+74.0%	–
Profit growth		-44.0%	-52.8%	-19.0%	+208.8%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+15.3%	–	–
Net profit	+5.8%	–	–
EPS	-0.3%	–	–
Share price	–	+37.9% (2y)	+11.3%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	34	49
Borrowings	17	14
Cash & equivalents	0	1
Total assets	65	75
Fixed assets	12	11
Capital work in progress	2	2
Investments	1	1
Receivables	14	24
Inventory	25	26
Payables	8	7

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	4	-7
Cash from investing	-2	-1
Cash from financing	-1	8
Capex	2	1
Free cash flow	1	-8

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	1.0%	2.2%
ROCE %	5.3%	5.1%
Debtor days	110	113
Inventory days	262	138
Payable days	79	38
Cash conversion cycle (days)	293	213
Working capital days	118	149

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
CONCORD	₹86 cr	36.4x	1.8x	5.0%	7.2%	6.7%	+15.3%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	CONCORD
BSE code	538965
ISIN	INE858L01010
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.